ClinicalTrials.gg
CompletedNCT05064930Updated Jul 7, 2023

The Efficacy of Single-strain Probiotics in Patients With Irritable Bowel Syndrome

An interventional study of Probiotic Bifidobacterium lactis and Probiotic Bacillus coagulans in Irritable Bowel Syndrome, sponsored by Nordic Biotic Sp. z o.o.. Completed at 1 site in Poland. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-07-07.

Sponsored by Nordic Biotic Sp. z o.o. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Irritable Bowel Syndrome with a site in Poland — 6 open to participants now, 6 under way, none of them phase 3. Irritable Bowel Syndrome · Poland.

Enrollment
14th of 24
120 · median 165
Started
2021
with 1 other
No phase
12 of 27
5 open now
Registered
17th of 27
by date
Lead sponsor
2 of 27
Nordic Biotic Sp. z o.o.

Among the 27 studies in Irritable Bowel Syndrome with a site in Poland, this one is the 14th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2021, is one of 12 with no phase, and was the 17th registered.

Irritable Bowel Syndrome

1,121 studies on the registry are indexed under Irritable Bowel Syndrome; 212 are open to participants now.

Browse Irritable Bowel Syndrome studies →

Open to participants now

6 of the 27 studies in Irritable Bowel Syndrome with a site in Poland are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 131 Irritable Bowel Syndrome studies recruiting now, 35 (27%) set no upper age limit and 86 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Irritable Bowel Syndrome with a site in Poland, or all of them as a file.
02

Study summary

Irritable bowel syndrome (IBS) is one of the most common, yet still not fully understood, gastrointestinal disorders in adults. One suspected etiology involves intestinal dysbiosis, i.e. both quantitative and qualitative alterations in intestinal microbiota composition, which affects the gut-brain axis. Probiotics are live microorganisms, which-administered at the right dose-are beneficial for human health; their mechanism of action involves modifying the gut microbiota. Clinical study reports document that probiotic administration is beneficial for patients with IBS. The ultimate clinical effects depend primarily on probiotic strain selection. Our research team evaluated a multi-strain probiotic formulation and a multi-strain synbiotic (a combination of probiotic strains with short-chain prebiotic fructooligosaccharides) formulation as part of two randomized placebo-controlled clinical trials in patients with IBS with predominant diarrhea. The results indicated a beneficial effect of these formulations on the clinical course of IBS assessed with the international IBS symptom severity scale (IBS-SSS), with each of the study formulations exhibiting efficacy in different fields. The formulation composed of a mixture of Bifidobacterium and Lactobacillus strains reduced the levels of pain and improved the quality of life, whereas the synbiotic formulation effectively improved bloating and had a beneficial effect on the general condition of the intestines. A systematic review and meta-analysis published in 2020 showed that high doses of single-strain formulations, particularly those containing Bifidobacterium or Lactobacillus strains, may be more effective in IBS patients. Other reports demonstrated a high efficacy of the new-generation probiotic Bacillus coagulans in IBS. Therefore, the main objective of this research project is to assess the efficacy of single-strain probiotics containing Bifidobacterium lactis or Bacillus coagulans in patients with IBS.

Read the detailed description

This is a randomized double-blind placebo-controlled trial included 120 adult patients, who had been diagnosed with IBS according to the Rome IV diagnostic criteria. The patients will receive orally a probiotic formulation containing Bifidobacterium lactis or Bacillus coagulans or placebo over a period of 12 weeks. Once the period of supplementation is completed, the patients will be followed-up for the subsequent 4 weeks. The patients included in the study will receive diaries, which they will complete daily. The patient's dairy will include information about the number of stools, stool consistency (assessed based on the Bristol Stool Form Scale) and IBS symptoms (abdominal pain, bloating, bowel urgency, and feeling of incomplete evacuation) rated in a 5-grade scale. The diary will also include information on any adverse events and the use of any new medications during the study. Once a week, the patients will be contacted by phone by interviewers who will collect the information recorded in the patient's diary.

During the first visit, the patients included in the study will be informed of the study procedure and educated on the phone exchanges with the interviewers. One week prior to study intervention, the patients will be asked to record their symptoms in their patient diaries every day. Subsequently, the patients will visit their study doctor every four weeks (from the beginning of the study intervention) in order to receive the next dose of the study formulation/placebo. During each study visit, the patients will be evaluated with the use of IBS-SSS and IBS Global Improvement Scale (IBS-GIS). The patients included in the study will undergo a hydrogen breath test for small intestinal bacterial overgrowth (SIBO) both prior to receiving the study formulation/placebo and 12 weeks later, after intervention is completed.

The study will last a total of 16 weeks from the moment the intervention is initiated (12 weeks of interventions and 4 weeks of follow-up).

03

Conditions studied

  • Irritable Bowel Syndrome

Keywords

  • Probiotics
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Caucasian males and females;
  2. Age from 18 to 70 years, inclusive;
  3. Good physical and mental condition assessed based on the patient's history and physical examination;
  4. Laboratory test results (blood tests, including blood chemistry and antibody tests; and urinalysis) within the normal limits for the local laboratory or considered clinically insignificant by the study investigator;
  5. A voluntarily provided written ;
  6. Being available throughout the duration of the study;
  7. Patients with IBS diagnosed based on the Rome IV criteria;
  8. Patients with any form of IBS of at least moderate severity assessed via the IBS-SSS (score >175).

Exclusion criteria

Exclusion Criteria:

  1. Cardiovascular disorders: uncontrolled hypertension (blood pressure > 170/100 mmHg), cerebrovascular disease;
  2. Severe respiratory disorders (asthma, )
  3. Liver or kidney disease and unexplained blood chemistry abnormalities: serum creatinine of more than twice the , serum aminotransferease ( or ALT) levels more than twice the upper limit of normal;
  4. Gastrointestinal disorders other than IBS (including gastroenteritis, celiac disease, and bacterial infections or parasitic infestations confirmed either clinically or endoscopically);
  5. Endocrine disorders, including diabetes (fasting blood glucose > 11 mmol/L) and serum thyroid stimulating hormone (TSH) levels above normal;
  6. Severe neurological conditions, with psychosis;
  7. ;
  8. Pregnancy or breastfeeding;
  9. to soy;
  10. Lactose intolerance that may explain the symptoms (i.e. the symptoms resolve or considerably subside in response to a lactose-free diet);
  11. The use of gastrointestinal motility stimulants or dietary fiber supplements during the 2 weeks preceding the clinical study;
  12. The use of antithrombotic agents;
  13. A surgical procedure scheduled during the course of the clinical study;
  14. Current probiotic use and refusal to undergo a 3-month ;
  15. Antibiotic therapy within the previous 3 months;
  16. The patients who receive antibiotics during the study will be excluded;
  17. Being included in another clinical study within the previous 3 months;
  18. History of alcohol or substance abuse.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Active comparator
    Bifidobacterium lactis

    Probiotic formula contains 5x109 Bifidobacterium lactis Nordbiotic™ BI040 colony forming units (CFU)/capsule

    Dietary Supplement: Probiotic Bifidobacterium lactis

  • Active comparator
    Bacillus coagulans

    Probiotic formula contains 2x109 Bacillus coagulans Nordbiotic™BC300 colony forming units (CFU)/capsule

    Dietary Supplement: Probiotic Bacillus coagulans

  • Placebo comparator
    Maltodextrin

    Maltodextrin (starch hydrolisate) as a compound presents in probiotic formula.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementProbiotic Bifidobacterium lactis

    The probiotic will be administered orally over a period of 12 weeks.

  • Dietary supplementProbiotic Bacillus coagulans

    The probiotic will be administered orally over a period of 12 weeks.

  • Dietary supplementPlacebo

    Maltodextrin as a placebo will be administered orally over a period of 12 weeks. The taste and appearance of the placebo will be similar to those of the probiotic formulation.

06

What researchers measure

Primary outcomes

  1. Changes in severity of IBS symptoms using IBS Severity Scoring System (IBS-SSS)

    IBS-SSS is a 5-question survey that asks: 1. the severity of abdominal pain, 2. frequency of abdominal pain, 3. severity of abdominal distention, 4.dissatisfaction with bowel habit, and 5. interference with quality of life over the past 10 days. Subjects respond to each question on a 100-point visual analogue scale. Each of the five question generates a maximum score of 100 point, and total scores can range from 0-500 with higher scores indicating severe symptoms. A decrease of 50 points is associated with a clinically meaningful improvement.

    Time frame: From baseline at 4, 8, 12 weeks of intervention, and 4 weeks (16 weeks of the study) after intervention

  2. Improvement of IBS global symptoms using Global Improvement Scale (IBS-GIS)

    IBS-Global Improvement Scale assesses IBS symptoms using a patient-defined 7 point Likert scale ranging from symptoms substantially worse to substantially improved. Patients answer the question "Have you felt any change in the severity of your symptoms over the past 7 days compared to how you felt before the medicine was given? The answers are recorded based on the 7-point scale: 1. = I feel that the symptoms have worsened significantly 2. = I feel that the symptoms have moderately worsened 3. = I feel that the symptoms have slightly worsened 4. = I feel no change 5. = I feel a slight improvement 6. = I feel moderate improvement 7. = I feel significant improvement IBS-GIS score indicates: improvement if is \>4 or worsening if is\<4, no change if is 4

    Time frame: From baseline at 4, 8, 12 weeks of intervention, and 4 weeks (16 weeks of the study) after intervention

Secondary outcomes

  1. Changes in number of stools

    The number of stools per day assessed before intervention and then 3 times a week

    Time frame: From baseline for 12 weeks of intervention, and for 4 weeks after intervention

  2. Changes in severity of pain

    The severity of pain assessed before intervention and then 3 times a week using a patient-defined 5 point Likert scale: point 0 - no pain, and 1-4 the severity of pain with higher scores indicating worse pain.

    Time frame: From baseline for 12 weeks of intervention, and for 4 weeks after intervention

  3. Changes in flatulence

    The severity of flatulence assessed before intervention and then 3 times a week using a patient-defined 5 point Likert scale: point 0 - no flatulence/abdominal distension, and 1-4 the severity of flatulence/abdominal distension with higher scores indicating worse pain.

    Time frame: From baseline for 12 weeks of intervention, and for 4 weeks after intervention

  4. Occurrence of side effects

    Side effects will be pointed in patient's dairy and collected by phone by interviewers.

    Time frame: From baseline for 12 weeks of intervention

  5. Changes in type of stools

    The type of stools analyzed before intervention and then 3 times a week. Type of stools assessed using the Bristol Stool Scale (BSS). BSS is designed to classify faeces into seven groups: type 1-2 indicate constipation, type 3-4 are "normal" stools; type 5-7 indicate diarrhea. The type of stool will be assessed with 7-point numerical scale (range 1-7).

    Time frame: From baseline for 12 weeks of intervention, and for 4 weeks after intervention

07

Study locations

1 site
  • Medical University of Lublin
    Lublin, Poland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Jun 2022, 9 months.

Of 52 industry-sponsored interventional studies with no phase under Irritable Bowel Syndrome, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's 9 months is below that.

Counting every sponsor, half of 360 studies reached it within 19 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2021
First posted
Oct 1, 2021
StartActual
Sep 1, 2021
Primary completionActual
Jun 30, 2022
CompletionActual
Jul 31, 2022
Last update
Jul 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05064930
Lead sponsor
Nordic Biotic Sp. z o.o.
Collaborators
Medical University of Lublin
Responsible party
Barbara Skrzydło-Radomańska (Profesor, MD, PhD, Nordic Biotic Sp. z o.o.) — Principal investigator
First posted
Oct 1, 2021
Start date
Sep 1, 2021
Primary completion
Jun 30, 2022
Completion
Jul 31, 2022
Last update
Jul 7, 2023

Study contacts

Barbara Skrzydło-Radomańska, MD, PhD
principal investigator · Medical University of Lublin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion